PARTICIPATING INVESTORS
The US Pathology Services Market:
$20B in 2024
Focused on small, localized healthcare service companies that are offing pathology services: A medical diagnostics service that analyzes patient samples to help doctors diagnose disease and choose treatment.
The Revenue Lines
A $10B market, anatomic pathology is the core service
Examining tissue under a microscope to identify and classify disease (e.g., detecting cancer). This creates stable, recurring revenue, paid per case by insurers, hospitals, and government healthcare programs.
Another $10B market, molecular pathology is an advanced layer
Analyzing DNA and other cellular markers to determine how a disease behaves and which therapies will work. Molecular testing is higher value per test, growing rapidly with the rise of personalized medicine.
Offering both services allows the company to capture more revenue per patient and deliver faster, more integrated results to physicians. The combined model produces a defensive base business with a high-growth upside, creating durable customer relationships and strong long-term economics.
Platform Deal General Description
Focused on small, localized healthcare service companies that are offing pathology services: A medical diagnostics service that analyzes patient samples to help doctors diagnose disease and choose treatment.
Criteria
Run Rate Revenue
$20-40M
Management Team
Engaged and look for growth
Adjusted EBITDA
Minimum 10%
Growth Opportunity – Actionable AI with quick financial returns
Pathology is a sweet spot for AI technology implementation, sitting at the frontier of AI in medical services
Current AI Development
Technology is early and emerging and requires significant “middleware” expertise, such as slide digitization and installation of FDA approved devices that both reduce labor costs (increasing margin) and increase revenues by expanding offerings to existing referral sources.
Pricing
Pricing (reimbursement rates): pathology services have been steady and are projected to remain so as many small pathology labs are reluctant to adopt new technologies both operationally and financially.
Highly fragmented market
There are over 600 independent physician-owned labs in the US that are small, undercapitalized and ripe for acquisition and improvement
Investment Thesis
1 | M&A Arbitrage
Start with a fast growing, AI focused business that has:
A
Experience in implementing the steps required to adopt AI tools as the become available
B
Sufficient capitalization and public stock as currency to acquire “unimproved” pathology labs
C
Highly fragmented market with plenty of acquisition targets. The primary targets have:
• Flat or low growing revenue
• Lower end of the profit spectrum with around 10% EBITDA
• Can be bcquired on a multiple of trailing 12-month EBITDA (projected to be 1-1.5 times revenues)
2 | Start Strong
Platform business brings proven revenue growth while generating positive EBITDA( adjusting for the pubco model)
3 | Large Existing Pipeline